Document is current

Any future updates will be listed below

MSI-H/dMMR-Tumoren: Pembrolizumab überzeugt in Erst- und Zweitlinie

Crossref DOI link: https://doi.org/10.1007/s15015-022-2954-8

Published Online: 2022-10-25

Published Print: 2022-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark